Streetbeat News

Earnings

MDB

MongoDB shares are trading lower following the company's announcement of weak guidance for both Q1 and the full fiscal year 2025, indicating potential challenges ahead.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:11 pm

MDB

MongoDB has issued its financial guidance for Q1 and the full year of fiscal 2025, projecting lower earnings and revenue than analysts expected. The company anticipates Q1 EPS to be between $0.34 and $0.39, versus the estimated $0.62, and revenue between $436M and $440M, compared to the expected $447.47M. For the full year, MongoDB forecasts EPS between $2.27 and $2.49, against the estimated $3.34, and revenue between $1.9B and $1.93B, lower than the $2.03B estimate. This guidance accounts for over $80 million of FY24 revenue from multi-year term licenses and unused Atlas commitments not expected to be realized in FY25.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:11 pm

OWLT

Owlet (NYSE:OWLT) reported Q4 2023 adjusted EPS of $(0.120), missing the $(0.040) estimate, with sales of $21.000M also missing the $21.160M estimate. This represents a 75% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:11 pm

SWBI

Smith & Wesson Brands (SWBI) reported Q3 2024 adjusted EPS of $0.190, surpassing the $0.100 estimate, with sales of $137.500M exceeding the $133.548M forecast. This represents a 6.56% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:10 pm

ONCY

Oncolytics Biotech (NASDAQ:ONCY) reported Q4 earnings, beating estimates with an EPS of $-0.04 against an expected $-0.11, despite revenue being down from the previous year. The company's past earnings performance saw a miss on EPS last quarter, leading to a 4.0% share price drop the following day.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 9:10 pm

LUMO

Lumos Pharma (NASDAQ:LUMO) reported Q4 earnings with an EPS of $-1.17, missing estimates by -2.0%. Revenue increased by $314 thousand year-over-year. Despite missing this quarter's earnings estimates, past performance shows a positive trend in share price following earnings beats.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 9:10 pm

LUMO

Lumos Pharma (NASDAQ:LUMO) reported Q4 2023 earnings with a GAAP EPS of $(1.170), missing estimates by 1.74%. However, their sales of $826,000 significantly exceeded expectations, marking a 61.33% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:09 pm

MRVL

Marvell Technology has provided guidance for Q1 2025, projecting adjusted EPS of $0.23 ± $0.05, which is below the estimated $0.40. Revenue is expected to be around $1.150B ± 5%, also falling short of the $1.371B estimate.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:08 pm

DOCU

DocuSign reported a 13% year-over-year increase in Q4 billings, indicating strong performance and growth.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:08 pm

SVV

Savers Value Village (NYSE:SVV) reported Q4 adjusted EPS of $0.15, missing the consensus estimate of $0.17. Quarterly sales were $382.76M, slightly below the estimate of $383.03M.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:08 pm